The earnings call highlighted strong revenue growth for Orladeyo, successful addition of new prescribers, and significant progress in clinical trials and financial performance, indicating positive momentum. However, challenges remain with the Medicare paid rate and potential royalty impacts. Overall, the positive developments significantly outweigh the challenges.

Company Guidance

During BioCryst's third quarter 2024 earnings call, the company reported a robust performance, highlighted by a 36% year-over-year increase in Orladeyo's quarterly revenue, reaching $116.3 million globally. The company emphasized its path to sustainable profitability, with an operating profit of $24.9 million excluding non-cash stock compensation, and cash flow positivity over $13 million for the quarter. Orladeyo's U.S. paid rate increased to 74.8%, with a commercial paid rate holding at 82%, and the Medicare rate improving by 3% to 55%. The company's 2024 revenue guidance for Orladeyo was tightened to $430-$435 million, while total company revenue guidance, including anticipated Rapivab sales, was set at $443-$448 million. BioCryst continues to advance its pipeline, with plans to submit regulatory submissions for pediatric Orladeyo in 2025 and initiate studies for BCX-17725 and avoralstat, targeting Netherton syndrome and diabetic macular edema, respectively.

Orladeyo Revenue Growth

Orladeyo achieved nearly 36% year-over-year growth in quarterly revenue, with $116.3 million in global revenue for the quarter.

New Prescribers and Market Expansion

The company added 67 new U.S. prescribers in the quarter, one of the best quarters in the last 2 years. U.S. start forms over the past 12 months are up almost 15% compared to the prior 12 months.

Phase I Study for BCX-17725

Initiated dosing in a Phase I healthy volunteer study for BCX-17725, targeting Netherton syndrome, marking the rapid delivery of the first protein therapeutic using the new protein platform technology.

Financial Performance and Profitability

Achieved an operating profit for the quarter of $24.9 million excluding noncash stock compensation, and positive net cash flow for the quarter of over $13 million.

Strong Cash Position and Independence

The company is in a strong financial position with $351.7 million in cash, and has achieved independence from capital markets.

---

BioCryst (BCRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2025	2024 (Q4)	-0.07 / -	-0.31	―	―	―
Nov 04, 2024	2024 (Q3)	-0.07 / -0.07	-0.19	63.16% (+0.12)
Aug 05, 2024	2024 (Q2)	-0.17 / -0.06	-0.4	85.00% (+0.34)
May 06, 2024	2024 (Q1)	-0.21 / -0.17	-0.28	39.29% (+0.11)
Feb 26, 2024	2023 (Q4)	-0.25 / -0.31	-0.38	18.42% (+0.07)
Nov 02, 2023	2023 (Q3)	-0.24 / -0.19	-0.23	17.39% (+0.04)
Aug 03, 2023	2023 (Q2)	-0.23 / -0.40	-0.32	-25.00% (-0.08)
May 03, 2023	2023 (Q1)	-0.30 / -0.28	-0.4	30.00% (+0.12)
Feb 21, 2023	2022 (Q4)	-0.17 / -0.38	-0.1	-280.00% (-0.28)
Nov 01, 2022	2022 (Q3)	-0.28 / -0.23	-0.33	30.30% (+0.10)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BCRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2024	$8.43	$7.35	-12.81%
Aug 05, 2024	$7.02	$7.51	+6.98%
May 06, 2024	$4.45	$5.27	+18.43%
Feb 26, 2024	$5.71	$5.79	+1.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---